|
|
|
ECTE - Echo Therapeutics, Inc.
Echo
Therapeutics, Inc. (ECTE) is a medical device and specialty
pharmaceutical company that develops and commercializes products for
diabetes care. The company's main product is the Symphony tCGM System,
a non-invasive, wireless, transdermal continuous glucose monitoring
system that provides real-time glucose monitoring for patients with
diabetes.
The Symphony tCGM System is designed to be pain-free
and easy to use, making it a potentially valuable tool for managing
diabetes. The device consists of a small wireless transmitter that is
attached to the skin and a handheld monitor that displays the
patient's glucose levels. The system also includes an optional alarm
feature that can alert patients when their glucose levels fall outside
of a predetermined range.
In addition to its glucose monitoring
system, Echo Therapeutics is developing a suite of specialty
pharmaceutical products for diabetes care. The company's pipeline
includes a topical anesthetic cream for use prior to insulin
injections and a topical treatment for diabetic foot ulcers.
Echo Therapeutics was founded in 2007 and is headquartered in Iselin,
New Jersey. The company is listed on the OTC Markets under the ticker
symbol ECTE. As of 2021, Echo Therapeutics has a small team of
employees and is focused on developing and commercializing its
Symphony tCGM System and other diabetes care products. The company
faces significant competition in the diabetes care market,
particularly from established players such as Abbott Laboratories,
Dexcom, and
|
|
|
|
|
